Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q Voorraadrapport

Marktkapitalisatie: US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Eiger BioPharmaceuticals' CEO is David Apelian, appointed in Dec 2022, has a tenure of 1.83 years. total yearly compensation is $1.48M, comprised of 42.3% salary and 57.7% bonuses, including company stock and options. directly owns 2.1% of the company’s shares, worth $263.77K. The average tenure of the management team and the board of directors is 1.7 years and 6.3 years respectively.

Belangrijke informatie

David Apelian

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris42.3%
Dienstverband CEO1.8yrs
Eigendom CEO2.1%
Management gemiddelde ambtstermijn1.7yrs
Gemiddelde ambtstermijn bestuur6.3yrs

Recente managementupdates

Recent updates

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 01
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Jan 04
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Dec 20
Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Oct 05

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

Sep 06

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

Jul 26

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Jul 20

Analyse CEO-vergoeding

Hoe is David Apelian's beloning veranderd ten opzichte van Eiger BioPharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2023US$1mUS$626k

-US$75m

Sep 30 2023n/an/a

-US$87m

Jun 30 2023n/an/a

-US$96m

Mar 31 2023n/an/a

-US$97m

Dec 31 2022US$204kUS$31k

-US$97m

Sep 30 2022n/an/a

-US$93m

Jun 30 2022n/an/a

-US$89m

Mar 31 2022n/an/a

-US$86m

Dec 31 2021US$149kn/a

-US$34m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$102kn/a

-US$65m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$2mUS$272k

-US$70m

Sep 30 2019n/an/a

-US$70m

Jun 30 2019n/an/a

-US$68m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$3mUS$514k

-US$52m

Sep 30 2018n/an/a

-US$47m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$40m

Dec 31 2017US$194kn/a

-US$42m

Compensatie versus markt: David's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD667.78K).

Compensatie versus inkomsten: David's compensation has increased whilst the company is unprofitable.

CEO

David Apelian (59 yo)

1.8yrs

Tenure

US$1,478,892

Compensatie

Dr. David Apelian, M.D., Ph D., MBA, served as Chief Executive Officer and Director of Bluesphere Bio, Inc. since July 2019. Dr. Apelian served as Chief Operating Officer and Executive Medical Officer at E...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Apelian
CEO & Director1.8yrsUS$1.48m2.1%
$ 263.8k
James Vollins
General Counsel1.5yrsUS$548.12k0.27%
$ 34.0k
Christopher Kurtz
Chief Technical Officer2.5yrsgeen gegevensgeen gegevens
Douglas Staut
Chief Restructuring Officerless than a yeargeen gegevensgeen gegevens

1.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: EIGR.Q's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Apelian
CEO & Director7.3yrsUS$1.48m2.1%
$ 263.8k
Thomas Dietz
Independent Chairman8.6yrsUS$170.00k0.36%
$ 45.6k
Amit Sachdev
Independent Director5.5yrsUS$67.50k0.099%
$ 12.5k
Lisa Kelly-Croswell
Independent Director2.3yrsUS$52.50k0%
$ 0
Stanley Rockson
Scientific Advisorno datageen gegevensgeen gegevens
Evan Loh
Independent Director7.1yrsUS$69.50k0.099%
$ 12.5k
Tracey McLaughlin
Scientific Advisorno datageen gegevensgeen gegevens
Kim Sablich
Director3.5yrsUS$57.00k0.077%
$ 9.6k

6.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: EIGR.Q's board of directors are considered experienced (6.3 years average tenure).